Elevance Health (ELV) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
6 Oct, 2026Scale and strategy
44.9M medical members across affiliated health plans and ~104M consumers served; footprint spans 24 Medicare markets and 24 Medicaid markets, including Puerto Rico.
Enterprise ambition: be a lifetime, trusted health partner by lowering healthcare costs and simplifying access, navigation and use.
Carelon served 92.4M consumers and processed 334.7M annual adjusted scripts on a rolling-12-month basis as of Q2 2026.
Governance and board
Board has 10 of 11 independent directors, a separate independent chair and CEO, and fully independent Audit, Compensation & Talent, Finance and Governance committees.
Board averages 64.5 years of age and 8.2 years of tenure; 8 of 11 directors are female and/or racially or ethnically diverse, and two independent directors joined in the past year.
Annual Board, committee and individual director evaluations are externally led; directors oversee refreshment, succession planning, enterprise risk and AI governance and use.
Shareholder safeguards include majority voting, proxy access, executive incentive clawbacks, stock ownership requirements and a policy against short sales, hedging and pledging.
Executive compensation
CEO target compensation was 79% long-term incentive/equity at target; other NEOs were 72%, with pay tied to financial, operational and strategic performance measures.
Long-term awards include performance stock units, restricted stock units and options; equity awards vest over three years, and Say-on-Pay received 96% support at the 2026 shareholder meeting.
Latest events from Elevance Health
- 2026 EPS guidance reaffirmed; 2027 growth targets supported by strong segment performance and AI investments.ELV
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue up 0.8%, adjusted EPS $7.45, guidance raised, $935M Medicare accrual excluded.ELV
Q2 2026 - Earnings outlook remains strong, with margin recovery and growth driven by Carelon and disciplined execution.ELV
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Strong financial results, board refresh, and strategic focus; all board proposals passed.ELV
AGM 2026 - Raised full-year adjusted EPS guidance after strong Q1 revenue, but net income declined.ELV
Q1 2026 - 2025 revenue hit $197.6B; 2026 EPS guidance is $25.50+ with margin recovery focus.ELV
Q4 2025 - Q3 2025 revenue up 12%, adjusted EPS $6.03, net income up 17%, and $3.3B returned to shareholders.ELV
Q3 2025 - Q2 2025 revenue up 14.3%, but earnings fell as medical costs pressured margins and guidance.ELV
Q2 2025 - 2024 revenue up 3% to $175.2B; 2025 EPS outlook raised, led by Carelon and cost focus.ELV
Q4 2024